Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Ras is a frequently activated oncogene in human cancers, yet its precise roles in transformation, growth arrest, and cell death are not fully understood.
• NORE1A (RASSF5), a direct Ras effector, functions as a tumor suppressor by inducing apoptosis and cell cycle arrest, but its mechanism and loss in tumors are unclear.

Purpose of the Study:

• To elucidate the mechanism by which NORE1A, a Ras effector and tumor suppressor, interacts with the SCF(β-TrCP) ubiquitin ligase complex.
• To investigate how Ras regulates this complex and its specific targets, particularly β-catenin, and to understand the implications for cancer signaling.

Main Methods:

• Co-immunoprecipitation to demonstrate the formation of a Ras-regulated complex between NORE1A and β-TrCP.
• Western blotting and proteasome inhibition assays to assess β-catenin and IκB degradation.
• Cellular assays to evaluate the impact of NORE1A levels on Ras signaling and the Wnt/β-catenin pathway.

Main Results:

• NORE1A directly binds to β-TrCP, forming a Ras-regulated complex that enhances SCF(β-TrCP) ligase activity.
• Ras, via NORE1A, specifically promotes the degradation of β-catenin by the 26 S proteasome, while leaving other SCF(β-TrCP) substrates like IκB unaffected.
• Cellular NORE1A levels determine the outcome of Ras signaling on the Wnt/β-catenin pathway.

Conclusions:

• A novel Ras signaling pathway is identified where Ras, through NORE1A, specifically targets β-catenin for degradation by the SCF(β-TrCP) ubiquitin ligase.
• The loss of NORE1A in tumors provides a mechanistic explanation for the context-dependent oncogenic or tumor-suppressive roles of β-TrCP.
• This discovery offers new insights into Ras-driven oncogenesis and potential therapeutic strategies targeting the NORE1A-SCF(β-TrCP)-β-catenin axis.